At its meeting on 8 May 2023, the Transparency Council adopted opinion No. 50/2023 on the appropriateness of granting reimbursement approvals for the drug Welireg (belzutifan) in von Hippel-Lindau syndrome.
At its meeting on 8 May 2023, the Transparency Council adopted opinion No. 50/2023 on the appropriateness of granting reimbursement approvals for the drug Welireg (belzutifan) in von Hippel-Lindau syndrome.